Vivus cuts 20 jobs as Qsymia sales disappoint again
This article was originally published in Scrip
Vivus earned $6.4m in third quarter 2013 net product revenue from sales of the prescription weight loss drug Qsymia (phentermine and topiramate), which is less than a $1m gain since the second quarter when Qsymia revenue totaled $5.5m and bested first quarter sales by $1.3m.
You may also be interested in...
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.